Bavarian Nordic — Februar 2016
-
Jeg har klippet indlæg fra 'debatten
' ind i den nye gruppe. MUFC, jeg håber, at det er ok. Jeg synes det er rart, at have forventede nyheder samlet her i den nye chatgruppe.Den 29. januar 2016 oprettede MUFC følgende i 'debatten':
-
De næste 6 måneder kommer der rigtig mange nyheder fra Bavarian. Der kommer nyheder omkring:
RSV vaccine fase I resultat
Imvamune ordrer + evt. godkendelse af frysetørret version
Ebola fase III resultat + evt. nye ordrer
Janssen partnerskabsaftaler
Start på fase II studie i CV301
samt Prostvac fase III interimsresultater
-
Tja, I må selv sætte linjeskift ind
-
Så gik IBB i +, var tidligere nede med over 2%
-
God morgen.
-
Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice
Poxvirus-based active immunotherapies mediate anti-tumor efficacy by triggering broad and durable Th1 dominated T cell responses against the tumor. While monotherapy significantly delays tumor growth, it often does not lead to complete tumor regression. It was hypothesized that the induced robust infiltration of IFNγ-producing T cells into the tumor could provoke an adaptive immune evasive response by the tumor through the upregulation of PD-L1 expression. In therapeutic CT26-HER-2 tumor models, MVA-BN-HER2 poxvirus immunotherapy resulted in significant tumor growth delay accompanied by a robust, tumor-infiltrating T cell response that was characterized by low to mid-levels of PD-1 expression on T cells. As hypothesized, this response was countered by significantly increased PD-L1 expression on the tumor and, unexpectedly, also on infiltrating T cells. Synergistic benefit of anti-tumor therapy was observed when MVA-BN-HER2 immunotherapy was combined with PD-1 immune checkpoint blockade. Interestingly, PD-1 blockade stimulated a second immune checkpoint molecule, LAG-3, to be expressed on T cells. Combining MVA-BN-HER2 immunotherapy with dual PD-1 plus LAG-3 blockade resulted in comprehensive tumor regression in all mice treated with the triple combination therapy. Subsequent rejection of tumors lacking the HER-2 antigen by treatment-responsive mice without further therapy six months after the original challenge demonstrated long lasting memory and suggested that effective T cell immunity to novel, non-targeted tumor antigens (antigen spread) had occurred. These data support the clinical investigation of this triple therapy regimen, especially in cancer patients harboring PD-L1neg/low tumors unlikely to benefit from immune checkpoint blockade alone.
(journals.plos.org)
-
math - MVA-BN tilhører Bavarian. BN står for Bavarian Nordic. Så ja, ser godt ud
-
Postate Cancer market to reach USD 13,6 Billion http://www.euroinvestor.dk/redirect.aspx?https%3A%2F%2Fwww.newswire.com%2Fnews%2Fprostate-cancer-market-to-reach-13-6-billion-revenue-growth-till-2021-8137555
-
Prostvac nævnes først af nye medicamenter der kan komme i spil
-
Enig OHW.
-
På EI er der rygter om snarlig EU Imvamune ordre
-
Ham der skriver "Mueller", er dygtig
-
Bava: Er der nogen som kan byde ind her? http://www.proinvestor.com/debat/74338
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind